Literature DB >> 27667530

5'-N-ethylcarboxamidoadenosine is not a paralog-specific Hsp90 inhibitor.

Shanshan Liu1, Timothy O Street1.   

Abstract

The molecular chaperone Hsp90 facilitates the folding and modulates activation of diverse substrate proteins. Unlike other heat shock proteins such as Hsp60 and Hsp70, Hsp90 plays critical regulatory roles by maintaining active states of kinases, many of which are overactive in cancer cells. Four Hsp90 paralogs are expressed in eukaryotic cells: Hsp90α/β (in the cytosol), Grp94 (in the endoplasmic reticulum), Trap1 (in mitochondria). Although numerous Hsp90 inhibitors are being tested in cancer clinical trials, little is known about why different Hsp90 inhibitors show specificity among Hsp90 paralogs. The paralog specificity of Hsp90 inhibitors is likely fundamental to inhibitor efficacy and side effects. In hopes of gaining insight into this issue we examined NECA (5'-N-ethylcarboxamidoadenosine), which has been claimed to be an example of a highly specific ligand that binds to one paralog, Grp94, but not cytosolic Hsp90. To our surprise we find that NECA inhibits many different Hsp90 proteins (Grp94, Hsp90α, Trap1, yeast Hsp82, bacterial HtpG). NMR experiments demonstrate that NECA can bind to the N-terminal domains of Grp94 and Hsp82. We use ATPase competition experiments to quantify the inhibitory power of NECA for different Hsp90 proteins. This scale: Hsp82 > Hsp90α > HtpG ≈ Grp94 > Trap1, ranks Grp94 as less sensitive to NECA inhibition. Because NECA is primarily used as an adenosine receptor agonist, our results also suggest that cell biological experiments utilizing NECA may have confounding effects from cytosolic Hsp90 inhibition.
© 2016 The Protein Society.

Entities:  

Keywords:  Grp94; Hsp90; NECA; chaperone; inhibitor

Mesh:

Substances:

Year:  2016        PMID: 27667530      PMCID: PMC5119565          DOI: 10.1002/pro.3049

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  27 in total

Review 1.  GRP94: An HSP90-like protein specialized for protein folding and quality control in the endoplasmic reticulum.

Authors:  Michal Marzec; Davide Eletto; Yair Argon
Journal:  Biochim Biophys Acta       Date:  2011-11-03

2.  Crowding Activates Heat Shock Protein 90.

Authors:  Jackson C Halpin; Bin Huang; Ming Sun; Timothy O Street
Journal:  J Biol Chem       Date:  2016-01-21       Impact factor: 5.157

Review 3.  Adenosine receptors as therapeutic targets.

Authors:  Kenneth A Jacobson; Zhan-Guo Gao
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

4.  Cytosolic chaperones influence the fate of a toxin dislocated from the endoplasmic reticulum.

Authors:  Robert A Spooner; Philip J Hart; Jonathan P Cook; Paola Pietroni; Christian Rogon; Jörg Höhfeld; Lynne M Roberts; J Michael Lord
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-06       Impact factor: 11.205

5.  Grp94, the endoplasmic reticulum Hsp90, has a similar solution conformation to cytosolic Hsp90 in the absence of nucleotide.

Authors:  Kristin A Krukenberg; Ulrike M K Böttcher; Daniel R Southworth; David A Agard
Journal:  Protein Sci       Date:  2009-09       Impact factor: 6.725

6.  Ligand interactions in the adenosine nucleotide-binding domain of the Hsp90 chaperone, GRP94. I. Evidence for allosteric regulation of ligand binding.

Authors:  M F Rosser; C V Nicchitta
Journal:  J Biol Chem       Date:  2000-07-28       Impact factor: 5.157

7.  Structure of the N-terminal domain of GRP94. Basis for ligand specificity and regulation.

Authors:  Karen L Soldano; Arif Jivan; Christopher V Nicchitta; Daniel T Gewirth
Journal:  J Biol Chem       Date:  2003-09-11       Impact factor: 5.157

8.  Intra- and intermonomer interactions are required to synergistically facilitate ATP hydrolysis in Hsp90.

Authors:  Christian N Cunningham; Kristin A Krukenberg; David A Agard
Journal:  J Biol Chem       Date:  2008-05-20       Impact factor: 5.157

Review 9.  Paralog Specific Hsp90 Inhibitors - A Brief History and a Bright Future.

Authors:  Daniel T Gewirth
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

10.  In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis.

Authors:  W M Obermann; H Sondermann; A A Russo; N P Pavletich; F U Hartl
Journal:  J Cell Biol       Date:  1998-11-16       Impact factor: 10.539

View more
  7 in total

1.  The endoplasmic reticulum (ER) chaperones BiP and Grp94 selectively associate when BiP is in the ADP conformation.

Authors:  Ming Sun; Judy L M Kotler; Shanshan Liu; Timothy O Street
Journal:  J Biol Chem       Date:  2019-02-20       Impact factor: 5.157

Review 2.  Adapting Secretory Proteostasis and Function Through the Unfolded Protein Response.

Authors:  Madeline Y Wong; Andrew S DiChiara; Patreece H Suen; Kenny Chen; Ngoc-Duc Doan; Matthew D Shoulders
Journal:  Curr Top Microbiol Immunol       Date:  2018       Impact factor: 4.291

3.  Structure Based Design of a Grp94-Selective Inhibitor: Exploiting a Key Residue in Grp94 To Optimize Paralog-Selective Binding.

Authors:  Nanette L S Que; Vincent M Crowley; Adam S Duerfeldt; Jinbo Zhao; Caitlin N Kent; Brian S J Blagg; Daniel T Gewirth
Journal:  J Med Chem       Date:  2018-03-20       Impact factor: 7.446

4.  NECA derivatives exploit the paralog-specific properties of the site 3 side pocket of Grp94, the endoplasmic reticulum Hsp90.

Authors:  John D Huck; Nanette L S Que; Robert M Immormino; Liza Shrestha; Tony Taldone; Gabriela Chiosis; Daniel T Gewirth
Journal:  J Biol Chem       Date:  2019-09-09       Impact factor: 5.157

5.  Biological Evaluation of 5'-(N-Ethylcarboxamido)adenosine Analogues as Grp94-Selective Inhibitors.

Authors:  Dilip K Tosh; Christopher M Brackett; Young-Hwan Jung; Zhan-Guo Gao; Monimoy Banerjee; Brian S J Blagg; Kenneth A Jacobson
Journal:  ACS Med Chem Lett       Date:  2021-03-01       Impact factor: 4.345

Review 6.  Combination of Anti-Cancer Drugs with Molecular Chaperone Inhibitors.

Authors:  Maxim Shevtsov; Gabriele Multhoff; Elena Mikhaylova; Atsushi Shibata; Irina Guzhova; Boris Margulis
Journal:  Int J Mol Sci       Date:  2019-10-24       Impact factor: 5.923

Review 7.  Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy.

Authors:  Ji Woong Kim; Yea Bin Cho; Sukmook Lee
Journal:  Cells       Date:  2021-03-17       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.